These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8704593)

  • 1. [The toxicological characteristics of the interaction of cholinolytics with aminostigmine--a new reversible cholinesterase inhibitor].
    Prozorovskiĭ VB; Sazonova AV
    Eksp Klin Farmakol; 1995; 58(5):57-61. PubMed ID: 8704593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Aminostigmine as a cholinesterase inhibitor and as an agent for treating poisonings by cholinergic blockers].
    Prozorovskiĭ VB; Livanov GA; Velikova VD; Afanas'ev VV; Pavlova LV
    Eksp Klin Farmakol; 1994; 57(5):13-5. PubMed ID: 7696893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Histamine blockers increase efficacy of specific antidote prophylaxis of intoxication by cholinesterase inhibitors in mice].
    Prozorovskiĭ VB; Skopichev VG; Ditiateva ZhA; Sazonova AV
    Eksp Klin Farmakol; 2000; 63(4):64-7. PubMed ID: 11022312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The pharmacological characteristics of the new anticholinesterase drug aminostigmine].
    Prozorovskiĭ VB; Pavlova LV; Suslova IM; Shchemeleva NI
    Eksp Klin Farmakol; 1992; 55(1):13-6. PubMed ID: 1305425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aminostigmine-a novel drug against home poisoning].
    Bonitenko II; Safronov GA; Sosiukin AE; Pershin VN; Shpilenia LS
    Klin Med (Mosk); 1996; 74(8):58-61. PubMed ID: 9036214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The comparative clinico-experimental characteristics of aminostigmine and galanthamine used for treating poisonings by choline-blocking substances].
    Prozorovskiĭ VB; Velikova VD; Pshenkina NN; Vasilenko ET
    Eksp Klin Farmakol; 1996; 59(1):64-7. PubMed ID: 8704639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New data on the pharmacokinetics of aminostigmine].
    Prozorovskiĭ VB; Chepur SV; Vorob'ev-Desiatovskiĭ NV; Panov PB
    Eksp Klin Farmakol; 1998; 61(5):46-9. PubMed ID: 9854634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Protection of mice by carbamates cholinesterase inhibitors against poisoning by armin and its dependence on certain physico-chemical indicators].
    Prozorovskiĭ VB; Pavlova LV; Suslova IM; Sazonova AV; Kokushkina AV
    Vopr Med Khim; 1999; 45(6):525-9. PubMed ID: 10761219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biochemical characteristics of aminostigmine--a new anticholinesterase agent].
    Prozorovskiĭ VB; Rozengart VI; Ardab'eva TV; Kugusheva LI; Suslova IM
    Biokhimiia; 1996 Apr; 61(4):690-6. PubMed ID: 8724787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acceleration of the restoration of conditioned reflexes following anesthesia using aminostigmine].
    Prozorovskiĭ VB; Iudkina NI
    Anesteziol Reanimatol; 1991; (1):25-6. PubMed ID: 1862957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possibility of usage of aminostigmine structural analogue for the treatment of toxic cognitive disorders.
    Fateev IV; Subbotina SN; Kurpyakova AF; Tyunin MA
    Bull Exp Biol Med; 2014 Jan; 156(3):353-6. PubMed ID: 24771374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bizerine: new anticholinesterase drug with selective gastrointestinal action].
    Prozorovskiĭ VB; Pavlova LV; Suslova IM; Sazonova AV; Shchemeleva NI
    Eksp Klin Farmakol; 2010 Aug; 73(8):14-6. PubMed ID: 20919551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bradycardia produced by pyridostigmine and physostigmine.
    Stein RD; Backman SB; Collier B; Polosa C
    Can J Anaesth; 1997 Dec; 44(12):1286-92. PubMed ID: 9429048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The pharmacokinetic interaction of cholinolytics and cholinesterase reactivators as a reflection of the modulation of their binding in blood plasma and in brain tissue].
    Elaeva NL; Predtechenskiĭ MB; Kul'bitskiĭ GN; Babaina EV; Trefilov VV
    Eksp Klin Farmakol; 1997; 60(4):64-7. PubMed ID: 9376763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of pyridostigmine bromide toxicity in mice by selected adrenergic agents and caffeine.
    Chaney LA; Rockhold RW; Mozingo JR; Hume AS; Moss JI
    Vet Hum Toxicol; 1997 Aug; 39(4):214-9. PubMed ID: 9251170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of pharmacologic prophylaxis with Panpal on acetylcholinesterase activity in the diaphragm and various parts of the brain in rats during treated and untreated Soman poisoning].
    Kassa J
    Cas Lek Cesk; 1998 May; 137(10):299-302. PubMed ID: 9650360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The influence of aminostigmine on the parameters of nonspecific resistance and immune system of the organism upon acute poisoning of benzyl 3-quinuclidylate].
    Zabrodskiĭ PF; Troshkin NM; Germanchuk VG; Sidel'nikova NM; Lim VG
    Eksp Klin Farmakol; 2005; 68(6):40-2. PubMed ID: 16405033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adamantyl tenocyclidines--adjuvant therapy in poisoning with organophosphorus compounds and carbamates.
    Skare D; Radić B; Lucić A; Peraica M; Domijan AM; Milković-Kraus S; Bradamante V; Jukić I
    Arch Toxicol; 2002 Apr; 76(3):173-7. PubMed ID: 11967623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of endogenous K+ in realizing the protective action of M-cholinolytics in chlorophos poisoning].
    Kosmachev AB; Kosmacheva IM; Fil'ko OA; Luleshov VI
    Eksp Klin Farmakol; 1992; 55(2):55-8. PubMed ID: 1422458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic analysis of the protection afforded by reversible inhibitors against irreversible inhibition of acetylcholinesterase by highly toxic organophosphorus compounds.
    Eckert S; Eyer P; Mückter H; Worek F
    Biochem Pharmacol; 2006 Jul; 72(3):344-57. PubMed ID: 16780806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.